Golin Health’s Post

🔍 Navigating Singapore's medical marketing landscape? Our comprehensive guide demystifies the Healthcare Service Act (HCSA) guidelines, ensuring your healthcare advertising is spot-on. Don't miss out on this crucial information. Dive in NOW 👉 https://lnkd.in/eydggWCz #firstpagedigital #digitalmarketing #medicalmarketing #medicalregulations

The National Healthcare CXO Summit is an invitation-only, premium Summit bringing leading senior level healthcare executives and innovative suppliers and solution providers together. The Summit’s content is aligned with key clinical trial challenges and interests, relevant market developments, and practical and progressive ideas and strategies adopted by successful pioneers. 22 October - 24 October 2023 Encore Boston Harbor Boston, MA USA #marcusevansgroup #nationalhealthcarecxosummit

A great way to share your research you are working on now, to benefit the broader health system #clinicalresearch #improvehealthoutcomes #researchinnovation

Health Information Management #HealthInformationmanagement

To celebrate B Corp month, our co-founder Elena Mills is looking forward to joining Lucy Eddowes (Costello Medical), Nick Leach (red thread | market access) and Rachel Hind (Passion Partnership CIC) on the panel for a FREE webinar aimed at healthcare agency employees and managers. Do join us if you'd like to hear about ways you can support the agency you work in or manage make sustainable changes for better business. Come with your questions at the ready for the panel! Registration link in comments. . . . #AgencyLife #BCorp #BCorpMonth #SustainableBusinesses #MedComms

Of course, as we/you, our members are active in every #EuHealthUnion pillar, the Specialists-Public Servants working in the Commission of the DG SANTE, see us at every meeting. Our faces become familiar next to the Federation of the Hospitals, the Researchers, the Pharma, the Medical Doctor, the poor and fragile Patient organisations (we are really supporting building smart patient organisations & earning kick-back fees for them), the Kinesists-Psysiotherapits, Ergotherapists, Nurses, Dieticians & Specialised Cook Federations, Med Tech manufacturers & innovators, etc. When we talk as last - we suprise everybody with the knowledge, facts, numbers, research data we can still bring thanks to our 12 ESPA Research Centers, Medical Universities & Vocational Education institutions and all that lies between.

Be sure to stop by and say hello to Darryl and myself. See what is going on in RCM. How would you REACT to a cyber security breach or downtime. Talk to us about what one organization went through

So, I am back from JPM Healthcare conference in SanFran.  It was a crazy week and a great experience. My 5 takeaways: (1) It is THE place to be for Pharma / Biotech partnering (2) Specifically for publicly traded organisations, presenting your company at the conference is a must to enforce your relevancy (3) The action is outside of the actual conference - majority of people don’t attend the conference but rather meet for business development, investment, or company analysis (4) Getting invited and attending the right evening receptions is even more critical than formal meetings. I had five receptions in one evening - could only make 3 of the 5 but they were worth it. (5) And MOST importantly, wear comfortable walking shoes and bring a good umbrella as you are moving between all the various hotels in central SanFran as you race to get to your next meeting. As mentioned previously, our BenevolentAI's Chairman & acting CEO, Francois Nader presented at the conference and did a fabulous job. He even mentioned my name as the Chief Revenue Officer in spearheading our way forward - quite an honour! The link to the recording is below.  In my PoV it is worth 20 minutes of your time. However, if you don't have time here is my recap: We are at the intersection of Pharma & Tech and  a pioneer & leader in AI-augmented drug discovery, enabled by the Benevolent Platform. We stand above our competition of AI in drug discovery as not only have we been doing it for 10 years, but we are also one of the rare platforms that has validated our approach via three ways : (1) Successful collaborations with AstraZeneca with TargetID and most recently Merck Healthcare KGaA with Chemistry. For AstraZeneca the products are in the pipeline and they're real. (2) We leveraged our indication expansion capabilities to identify Eli Lilly and Company's rheumatoid arthritis drug Olumiant (baricitinib) as a potential treatment for COVID-19, which received an emergency use authorisation from the US FDA in 2020; full approval in May 2022. (3) Our platform has generated 5 wholly owned products in a pipeline that looks like a traditional Biotech. Our lead asset BEN-8744 is an oral PDE10 inhibitor in Phase I which is a potential first-in-class option for ulcerative colitis. Our Business model offers multiple routes for value creation. In addition to our high potential R&D pipeline and our leading E2E Drug Discovery solutions mentioned above, we have a new expansion opportunity through suite of Knowledge Exploration tools that acting as a co-pilot for scientists, leverages bio-specific natural language processing (NLP) and large language models (LLM) to surface data, perform analysis, and give scientific recommendations to drive new insights and increase productivity. So, as you can see from above, this is a very exciting time for BenevolentAI and I am thrilled to be part of the journey! #JPM2024 #drugdiscovery #aidrugdiscovery #generativeai #researchanddevelopment